Open AccessManagement of acute vertigo with betahistine
Author(s) -
Renuka Bradoo,
Nupur Kapoor Nerurkar,
J. B. Mhapankar,
Sheetal Patil,
D. G. Kute
Publication year - 2000
Publication title -
indian journal of otolaryngology and head and neck surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.229
H-Index - 22
eISSN - 2231-3796
pISSN - 0973-7707
DOI - 10.1007/bf03000335
Subject(s) - vertigo , betahistine , medicine , tolerability , nausea , vomiting , tinnitus , anesthesia , otorhinolaryngology , sedation , prospective cohort study , surgery , adverse effect , audiology
This open, prospective study was carried out in 29 outpatients of vertigo with Betahistine treatment at a dose of 16 mg three times daily far a maximum treatment period of 6 weeks or earlier until remission of vertigo attacks. The evaluations were carried out based on three parameters such as frequency, duration, and severity of vertigo attacks. Betahistino showed a significant improvement in the three parameters of frequency, duration and severity of vertigo attacks. Associated symptoms such as tinnitus, nausea, vomiting, headache, faintness showed a significant improvement with the therapy. Subgroup analysis showed a significant improvement of patients with severe and incapacitating verlign attaeks at baseline. Thus, this study proves excellent efficacy and goad tolerability of Betahistine as an anti-vertigo drug at a dose of 16 mg three times daily and gives a new insight for controlling acute or severe vertigo attacks without causing sedation.